Clinical Trials Directory

Trials / Completed

CompletedNCT00469443

Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC

A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
330 (estimated)
Sponsor
Hellenic Oncology Research Group · Academic / Other
Sex
All
Age
18 Years – 72 Years
Healthy volunteers
Not accepted

Summary

This phase III study will compare two combinations of irinotecan, Folfiri versus Xeliri, with the addition of Avastin as 1st line treatment of colorectal cancer.

Detailed description

There is no data of comparison for Folfiri and Xeliri regimens. The reported data demonstrated that the addition of Avastin in the combination of irinotecan/bolus 5-FU/LV has significant improvement of overall survival. Further analysis of these results showed that patients receiving irinotecan in combination with Avastin, as 1st line treatment and oxaliplatin with Avastin, as second line treatment, have median overall survival 25, 1 months, which is the longest survival that has been reported.

Conditions

Interventions

TypeNameDescription
DRUGIrinotecanIrinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
DRUG5-Fluorouracil5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
DRUGLeucovorinLeucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
DRUGCapecitabineCapecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
DRUGBevacizumabBevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
DRUGBevacizumabBevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
DRUGIrinotecanIrinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles

Timeline

Start date
2006-12-01
Primary completion
2010-02-01
Completion
2010-02-01
First posted
2007-05-04
Last updated
2010-08-19

Locations

8 sites across 1 country: Greece

Source: ClinicalTrials.gov record NCT00469443. Inclusion in this directory is not an endorsement.